121 related articles for article (PubMed ID: 33743542)
1. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer.
Khalvandi A; Abolhasani M; Madjd Z; Shekarabi M; Kourosh-Arami M; Mohsenzadegan M
APMIS; 2021 Jun; 129(6):291-303. PubMed ID: 33743542
[TBL] [Abstract][Full Text] [Related]
2. Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis.
Khalvandi A; Abolhasani M; Madjd Z; Sharifi L; Bakhshi P; Mohsenzadegan M
World J Urol; 2021 Jun; 39(6):1831-1843. PubMed ID: 32772147
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.
Yin B; Zeng Y; Wang X; Liu G; Zhang M; Song Y
Int J Clin Exp Pathol; 2014; 7(7):4112-9. PubMed ID: 25120790
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue.
Hudolin T; Juretic A; Spagnoli GC; Pasini J; Bandic D; Heberer M; Kosicek M; Cacic M
Prostate; 2006 Jan; 66(1):13-8. PubMed ID: 16114059
[TBL] [Abstract][Full Text] [Related]
5. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.
Taeb J; Asgari M; Abolhasani M; Farajollahi MM; Madjd Z
Pathol Res Pract; 2014 Jan; 210(1):18-23. PubMed ID: 24183365
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M
Tumori; 2014; 100(1):60-8. PubMed ID: 24675493
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.
Kalantari E; Abolhasani M; Roudi R; Farajollahi MM; Farhad S; Madjd Z; Askarian-Amiri S; Mohsenzadegan M
Int J Exp Pathol; 2019 Apr; 100(2):123-132. PubMed ID: 31090157
[TBL] [Abstract][Full Text] [Related]
8. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer.
Laban S; Atanackovic D; Luetkens T; Knecht R; Busch CJ; Freytag M; Spagnoli G; Ritter G; Hoffmann TK; Knuth A; Sauter G; Wilczak W; Blessmann M; Borgmann K; Muenscher A; Clauditz TS
Int J Cancer; 2014 Sep; 135(5):1142-52. PubMed ID: 24482145
[TBL] [Abstract][Full Text] [Related]
10. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
11. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer.
von Boehmer L; Keller L; Mortezavi A; Provenzano M; Sais G; Hermanns T; Sulser T; Jungbluth AA; Old LJ; Kristiansen G; van den Broek M; Moch H; Knuth A; Wild PJ
PLoS One; 2011; 6(7):e21366. PubMed ID: 21754986
[TBL] [Abstract][Full Text] [Related]
12. Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.
Lerut E; Van Poppel H; Joniau S; Gruselle O; Coche T; Therasse P
Int J Clin Exp Pathol; 2015; 8(8):9522-32. PubMed ID: 26464715
[TBL] [Abstract][Full Text] [Related]
13. Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy.
Izumi K; Li Y; Zheng Y; Gordetsky J; Yao JL; Miyamoto H
Hum Pathol; 2012 Nov; 43(11):1991-2000. PubMed ID: 22617231
[TBL] [Abstract][Full Text] [Related]
14. Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.
Wong KK; Hussain FA; Loo SK; López JI
APMIS; 2017 Dec; 125(12):1092-1101. PubMed ID: 28972294
[TBL] [Abstract][Full Text] [Related]
15. MAGE-A3 is highly expressed in a subset of colorectal cancer patients.
Shantha Kumara HM; Grieco MJ; Caballero OL; Su T; Ahmed A; Ritter E; Gnjatic S; Cekic V; Old LJ; Simpson AJ; Cordon-Cardo C; Whelan RL
Cancer Immun; 2012; 12():16. PubMed ID: 23390371
[TBL] [Abstract][Full Text] [Related]
16. Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma.
Wang M; Li J; Wang L; Chen X; Zhang Z; Yue D; Ping Y; Shi X; Huang L; Zhang T; Yang L; Zhao Y; Ma X; Li D; Fan Z; Zhao L; Tang Z; Zhai W; Zhang B; Zhang Y
Int J Clin Exp Pathol; 2015; 8(4):3513-28. PubMed ID: 26097535
[TBL] [Abstract][Full Text] [Related]
17. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
19. Melanoma antigen encoding gene-A3 expression, its clinical significance, and its risk of developing acute myeloid leukemia.
Makhlouf MM
J Investig Med; 2011 Oct; 59(7):1131-6. PubMed ID: 21804405
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
Assi J; Srivastava G; Matta A; MacMillan C; Ralhan R; Walfish PG
PLoS One; 2015; 10(2):e0107586. PubMed ID: 25695234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
